SCIO 469 hydrochloride

Product Description

SCIO 469 hydrochloride is a selective, ATP-competitive p38 inhibitor (IC₅₀ = 9 nM for p38α in vitro). Displays approximately 10-fold selectivity for p38α over p38β and 2000-fold selectivity for p38α over 20 other kinases. Reduces p38α phosphorylation in multiple myeloma cells in vitro and in vivo; activity results in decreased tumor burden and angiogenesis in murine models of multiple myeloma. Also enhances bortezomib-induced cytotoxicity against multiple myeloma cells.

Solubility

Preparing Stock Solutions for SCIO 469 hydrochloride

The following data is based on the product molecular weight 549.46

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.82 mL	9.10 mL	18.20 mL
5 mM	0.36 mL	1.82 mL	3.64 mL
10 mM	0.18 mL	0.91 mL	1.82 mL
50 mM	0.04 mL	0.18 mL	0.36 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Giafis Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res. 2006 PMID: 16818652
• Vanderkerken Inhibition of p38α mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res. 2007 PMID: 17495322
• Hideshima p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 PMID: 15480425